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Rare sarcomere protein variants cause dominant hypertrophic and dilated cardiomyopathies. To evaluate whether allelic variants in
eight sarcomere genes are associated with cardiac morphology and function in the community, we sequenced 3,600 individuals from
the Framingham Heart Study (FHS) and Jackson Heart Study (JHS) cohorts. Out of the total, 11.2% of individuals had one or more
rare nonsynonymous sarcomere variants. The prevalence of likely pathogenic sarcomere variants was 0.6%, twice the previous estimates;
however, only four of the 22 individuals had clinical manifestations of hypertrophic cardiomyopathy. Rare sarcomere variants were asso-
ciated with an increased risk for adverse cardiovascular events (hazard ratio: 2.3) in the FHS cohort, suggesting that cardiovascular risk
assessment in the general population can benefit from rare variant analysis.More than 1,000 sarcomere protein gene variants that are
thought to cause dilated cardiomyopathy (MIM 115200)
or hypertrophic cardiomyopathy (MIM 192600) have
been identified in familial cardiomyopathies.1 Studies of
families ascertained on an index case have led to esti-
mates that that disease penetrance of such mutations is
greater than 95%.2 Next-generation-targeted resequencing
enables assessment of the full allelic spectrum of disease
genes in large cohorts. This study assessed the burden
of structural cardiovascular disease conferred by rare
variants in eight sarcomere protein genes in the general
community.
Sarcomere genes ACTC1 (MIM 102540), MYBPC3 (MIM
600958), MYH7 (MIM 160760), MYL2 (MIM 160781),
MYL3 (MIM 160790), TNNI3 (MIM 191044), TNNT2
(MIM 191045), and TPM1 (MIM 191010) were sequenced
in 1,637 unrelated individuals in the Offspring cohort of
the Framingham Heart Study3 and 1,963 unrelated indi-
viduals from the Jackson Heart Study cohort4 (Table S1
available online). These studies were performed with
protocols approved by FHS, JHS, and institutional ethics
committees and with informed consent. FHS is a three-
generation prospective, community-based family study
to identify the factors that contribute to cardiovascular
disease. In 1948, researchers recruited 5,209 men and1Department of Genetics, Harvard Medical School, Boston, MA 02115, USA
Cambridge, MA 02142, USA; 3Center for Human Genetic Research, Massachus
Medicine, Brigham and Women’s Hospital, Boston, MA 02115, USA; 5Nationa
MA 01702, USA; 6Departments of Cardiology and Preventive Medicine, Bosto
Molecular Medicine, Partners Center for Personalized Genetic Medicine, Ca
School of Public Health, Boston, MA 02118, USA; 9Department of Medicine, U
State University, Jackson, MS 39217, USA; 11Cardiology Division, Massachu
Research, National Heart, Lung, and Blood Institute, Bethesda, MD 20892, U
Medical Center, Jackson, MS 39216, USA; 14Divisions of Genetics and End
02115, USA; 15Department of Pathology, Harvard Medical School, Boston, M
Hughes Medical Institute, Chevy Chase, MD 20815, USA
*Correspondence: cseidman@genetics.med.harvard.edu
http://dx.doi.org/10.1016/j.ajhg.2012.07.017. 2012 by The American Societ
The Americanwomen between the ages of 30 and 62 who had not yet
developed cardiovascular disease from the town of Fra-
mingham, Massachusetts. The Offspring cohort consists
of 5,124 of the original participants’ adult children and
their spouses enrolled in 1971. FHS participants are
primarily of European ancestry. JHS is a large, commu-
nity-based observational study whose participants were
recruited from urban and rural areas of the Jackson,
Mississippi, metropolitan statistical area (MSA). The final
cohort of 5,301 participants includes 6.59% of all African
American Jackson MSA residents, aged 35–84.
Targeted genes were selected with a custom designed
hybrid capture array5 and then sequenced with an
Illumina HiSeq. Sequence reads were first aligned to
human genome assembly hg19 with the Burrows-Wheeler
Aligner6 and then, in accordance with previously described
procedures,7 recalibrated with the Genome Analysis Tool-
kit (GATK) and used for variant calling by the Unified
Genotyper module of the GATK and snpEff. Samples
from analysis with below 95% concordance with prior
dbGAP SNP array data, with less than 50% of targeted
bases covered to 203, or with a high number of singleton
variants were removed. Eighty percent of the target
bases were covered with at least 203 depth of coverage
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Pathogenicity of variants was evaluated with two
metrics: variant classification rules established by a Clinical
Laboratory Improvement Amendments (CLIA)-approved
laboratory variant calling algorithm (Partner’s Laboratory
for Molecular Medicine) and the PolyPhen HCM algo-
rithm,7 each of which classify variants as pathogenic,
benign, or having unknown significance.
Statistical analysis was performed with the R software
package unless otherwise noted. Significance of differences
between mean values and slopes of linear regression were
assessed using the t test statistic and only positive results
are reported.
Across the two cohorts, 11.2% of individuals had one
or more rare (MAF < 1%) nonsynonymous variants
(missense, nonsense, indels, and splice variants; Tables S2
and S3). Three individuals in the FHS cohort and 19 in
the JHS cohort had multiple rare nonsynonymous sarco-
mere variants. The frequency of rare nonsynonymous
sarcomere variants was proportional to protein length,
with the exception of MYBPC3 and MYL3, in which such
variants were overrepresented (p < 0.0001). This might
be due to underlying differences in genomic architecture.
The overall frequency of rare nonsynonymous sarcomere
variants was approximately the same in the FHS and JHS
cohorts (Figure S1). The prevalence of individuals with
rare known or likely pathogenic sarcomere variants based
on the Laboratory for Molecular Medicine criteria was
14 of 1,637 sequenced FHS participants and 8 of 1,963
sequenced JHS participants (Table S4). On the basis of
these findings, we estimate that 0.85% of the European
Americans and 0.4% of African Americans carry a sarco-
mere variant defined as known or likely to be pathogenic,
higher proportions than previously anticipated.8
We considered whether there was unrecognized stratifi-
cation of subjects with and without rare sarcomere variants
by testing for association between rare variant carrier status
and measures of ancestry differences. Using common vari-
ants that were genotyped in each cohort and deposited
into dbGaP, we computed the top ten principal compo-
nents of genetic variation with the EIGENSTRAT software
package for each distribution.9 Logistic regression of carrier
status on each of the principal components revealed no
evidence of statistical association between ancestry, at least
informed by common variants, and the presence of a rare
sarcomere gene variant (Figures S2 and S3) as association
results of the 20 tests were consistent with the null distri-
bution (one result, p < 0.05; the remainder, p > 0.1).
In addition, because rare variant stratification might not
be well captured by methods to detect stratification for
common variants, we selected a set of comparably sized
genes with no prior evidence for involvement in cardiac
morphology as negative controls and repeated our original
analysis based on rare variants discovered in those genes
using an empirical permutation as follows: p values were
computed for 10,000 sets of 8 genes randomly selected
from 30 genes included in the targeted sequencing of these
cohorts. The 30 control genes used in the permutation514 The American Journal of Human Genetics 91, 513–519, Septembanalysis (INS, KCNQ5, ANK2, CACNA1C, CAV3, KCNE1,
KCNE2, KCNH2, KCNJ2, NOS1AP, AKAP9, ATP1B1,
CNOT1, GINS3, LIG3, LITAF, NDRG4, RNF207, SCN4B,
ARL4D, ARL6, BBS1, BBS10, BBS12, BBS2, BBS4, BBS5,
BBS7, BBS9, and CCDC28B) were selected because each is
known or presumed to be pathogenic for either cardiac
electrophysiological phenotypes or anthropomorphic dis-
orders. These genes are not known to alter cardiac dimen-
sions. All reported p values were robust to this analysis.
To assess the burden of sarcomere related pathophysi-
ology, we assessed cardiac structure and function by using
echocardiography. For our analysis, we examined maxi-
mum left ventricular diastolic wall thickness (LVWT), left
ventricular diastolic diameter (LVDD), left atrial diameter
(LAD), and fractional shortening (FS). FHS individuals
had between one and five echocardiograms measured in
M-mode over a 25 year period.10 Where multiple echocar-
diograms are available, the most recent observation was
analyzed as cardiac dimensions increase with age. Only
a single 2D echocardiography study was available for the
JHS cohort, and this echocardiography study was assessed
for the same parameters.11 Dimensions were scaled by each
individual’s height to increase comparability across indi-
viduals as is standard practice in epidemiological echocar-
diography studies.12,13
The subset of traditional FHS physiologic risk factors14
previously associated with increased cardiac dimensions
was considered in these analyses: hyperlipidemia (choles-
terol > 240 mg/dl, HDL < 40 mg/dl, triglycerides >
150 mg/dl), hypertension (systolic blood pressure R
140 mmHg or diastolic blood pressure R 90 mmHg),
obesity (body mass index > 30), and diabetes (fasting
glucose R 126 mg/dl).15–18 Smoking has not been previ-
ously associated with increased cardiac dimensions and
was not considered. Phenotypes in the cohorts were strat-
ified by genotype and presence of two or more physiologic
risk factors (Table 1; Table S5 provides same data without
scaling for height). Physiological risk stratification in the
FHS cohort was assessed for each individual at the earliest
exam between ages 35 and 50. FHS individuals who did not
have a physical exam in that period were not considered
for the risk-stratified analyses to control for the effects of
aging. Physiological risk stratification in the JHS cohort
was assessed at the first exam.
Significant increases in LVWT and LAD were observed
among individuals carrying one or more rare sarcomere
variant (Table 1). LVWT was increased by 5% and 2% for
the FHS and JHS cohorts, respectively (p < 0.01, p < 0.05,
Table 1) in individuals with one or more rare nonsynony-
mous sarcomere variants compared to individuals with
no variants or physiologic risk factors. Individuals with
sarcomere variants of known or likely pathogenicity had
an 8.6% increased wall thickness in the FHS population
(p < 0.05) but not in the JHS population. This observation
might be accounted for by the fact that, historically, far
more resources have been dedicated to discovery of patho-
genic cardiomyopathy variants in populations of Europeaner 7, 2012
Table 1. Stratified Summary of Mean Scaled Echocardiography Measurements
Framingham Heart Study Jackson Heart Study
Nb Age Female LVWTc LVDDc LADc Nb Age Female LVWTc LVDDc LADc
No risk factorsa 855 58.3 (9.2) 63% 0.058 (0.007) 0.284 (0.025) 0.230 (0.028) 972 55.5 (12.7) 58% 0.055 (0.011) 0.285 (0.028) 0.205 (0.027)
R1 sarcomere variant 158 59.7 (9.4) 43% 0.060** (0.007) 0.285 (0.025) 0.236* (0.028) 244 57.9 (11.8) 62% 0.056* (0.010) 0.287 (0.028) 0.211** (0.025)
MYBPC3 92 59.3 46% 0.059 0.287 0.239** 186 58.6 61% 0.056* 0.288 0.212***
MYH7 36 59.4 39% 0.058 0.283 0.235 42 57.2 79% 0.054 0.288 0.208
MYL3 12 61.8 42% 0.061 0.278 0.231 8 56.3 57% 0.057 0.278 0.204
MYL2 7 61.7 50% 0.061 0.284 0.232 4 58.7 100% 0.058 0.293 0.211
TNNT2 6 57.0 50% 0.064 0.279 0.237 7 51.8 25% 0.053 0.294 0.207
TPM1 3 65.7 0% 0.058 0.284 0.206 6 55.0 40% 0.063 0.298 0.197
ACTC1 2 57.0 50% 0.069 0.267 0.234 0
TNNI3 2 61.5 50% 0.060 0.286 0.226 2 0.065 0.247 0.207
LMM (likely) pathogenic 14 63.0 (10.5) 38% 0.063* (0.007) 0.286 (0.034) 0.235 (0.028) 8 54.0 (14.1) 50% 0.054 (0.009) 0.287 (0.024) 0.209 (0.029)
PolyPhen HCM pathogenic 30 61.4 (9.2) 42% 0.061 (0.009) 0.279 (0.029) 0.226 (0.029) 26 59.0 (13.3) 59% 0.054 (0.009) 0.287 (0.024) 0.206 (0.025)
LMM benign 35 59.2 (9.4) 32% 0.060 (0.009) 0.288 (0.025) 0.246*** (0.027) 105 59.5 (11.9) 64% 0.056 (0.009) 0.291 (0.029) 0.214*** (0.025)
PolyPhen HCM benign 51 59.7 (9.4) 47% 0.059 (0.006) 0.286 (0.024) 0.242** (0.028) 85 59.3 (11.6) 66% 0.057 (0.011) 0.288 (0.023) 0.209 (0.023)
R2 physiologic risk factorsa 575 62.1 (9.1) 35% 0.061*** (0.008) 0.290*** (0.029) 0.246*** (0.032) 777 58.7 (11.0) 64% 0.058*** (0.010) 0.291*** (0.028) 0.213*** (0.029)
R1 sarcomere variant þ R2
physiologic risk factorsa
62 61.3 (10.2) 32% 0.061*** (0.007) 0.290* (0.022) 0.245*** (0.027) 97 59.5 (11.1) 64% 0.059*** (0.010) 0.288 (0.027) 0.215*** (0.023)
Significance is denoted as follows: *p < 0.05; **p < 0.01; ***p < 0.001. The following abbreviations are used: LVDD, left ventricular diastolic diameter; and LAD, left atrial diameter.
aPhysiologic risk factors include hyperlipidemia, hypertension, obesity, and diabetes. Standard deviations for this group are listed parenthetically.
bN is number of individuals.
cMeasurements (in mm) scaled by individuals’ heights (in cm) of left ventricular wall thickness (LVWT).
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ancestry than populations of African ancestry, underlying
differences in genomic architecture19 or the availability of
more extensive longitudinal data in FHS compared to
JHS. Individuals with either physiologic or a combination
of physiologic and genetic risk factors similarly had an
increase in left ventricular dimensions in both populations.
LAD was increased by 3% in FHS and JHS participants
with rare sarcomere variants compared to participants
without sarcomere variants or physiologic risk factors
(Table 1; p < 0.05, FHS; p < 0.01 JHS). Left atrial volume
is often increased in hypertrophic cardiomyopathy because
of ventricular diastolic dysfunction that is caused by
sarcomere protein mutations. Increased left atrial volume
is associated with an increase in adverse cardiovascular
events in patients with hypertrophic cardiomyopathy or
other cardiovascular conditions.20,21 Increased LAD was
significantly increased in cohort participantswithMYBPC3
variants and with variants classified as benign, the two
largest subgroups of variants (Table 1). Whether these
data imply a subtle impact of sarcomere variants on
diastolic function, misclassification of some variants as
benign, or an imprecise assessment of atrial size is unclear.
Out of 22 individuals with variants previously identified
in the literature as likely to be pathogenic, only four had
clinical criteria for HCM: two had LVWT >12 mm and
two had EKG criteria for LVH22. This might reflect a lower
sensitivity of population screening echocardiograms or a
lower disease penetrance in the general population com-
pared to previously studied HCM families.
We sought to further evaluate the potential pathoge-
nicity of rare nonsynonymous sarcomere variants by com-
paring the two tails of the phenotype distributions with
burden testing. Continuous phenotypes were transformed
to dichotomous variables by comparing the top and
bottom quartiles of the distribution. Because the variants
were too rare to be evaluated individually, we pooled vari-
ants by gene and computed the following statistical tests
with the Plink/Seq software package: burden testing of
cases compared to controls, C-alpha, count of case-unique
rare alleles, variable threshold test, frequency-weighted
test, and sum of single-site statistics. Although some of
these tests are designed to be sensitive to unusual distribu-
tions of rare variants,23,24 none produced a statistically
significant result (Figure S4). This is probably due to the
small number of individuals with pathogenic variants in
the tails of the distribution.
We additionally considered the potential pathogenicity
of nine common protein-altering variants with MAF
between 1% and 10% in either of the two populations
and examined their frequency and associated phenotypes
individually in FHS and JHS (Table S6). Analysis was done
by individual variant, rather than with a pooled approach.
No common variants were significantly associated with
measures of cardiac morphology when considering the
top and bottom quartiles as a dichotomous variable. While
considering left ventricular parameters as a continuous
variable, one variant, rs3729823 (MYH7 c.4472C>G516 The American Journal of Human Genetics 91, 513–519, Septemb[p.Ser1491Cys]; RefSeq: NM_000257.2), was associated
with increased fractional shortening in JHS (FS: 0.44, p ¼
0.001, n ¼ 12) but not in FHS.
We considered the combination of 11 low frequency
(0.5%–1%) or common variants (1%–10%) in addition to
a rare variant (Table S6). Thirty JHS individuals and two FHS
individuals shared SNP rs3729799 (MYBPC3 c.3004C>T
[p.Arg1002Trp]; RefSeq: NM_000256.3). Four of these JHS
participants carried a second rare sarcomere variant, all of
which occurred in MYBPC3 (c.2939G>A [p.Arg980His];
c.2914C>T [p.Arg972Trp]; c.646G>A [p.Ala216Thr]; and
c.3682C>T [p.Arg1228Cys]; RefSeq: NM_000256.3). This
combination was associated with a 14% decreased LVWT
(8.1 mm, p < 106) compared to individuals without
genetic or physiologic risk factors. These four individuals
also had a 14% decreased LVWT when compared to the
26 JHS individuals who shared one of the four rare sarco-
mere variants but lacked rs3729799 (p < 104) and a 15%
decreased LVWT in comparison to the 26 JHS individuals
with rs3729799 but no other rare sarcomere variants (p <
105). This observationmight imply that multiple variants
can have more effect on cardiac morphology than each
alone.
Given that the FHS cohort had multiple echocardio-
graphic evaluations over time, we had the opportunity to
evaluate the burden of sarcomere variants longitudinally.
Rare variants were associated with increased risk for greater
left ventricular dimensions with advancing age (Figures 1A
and 1B). A linear one way within groups ANOVA model
was constructed that predicted LVWT scaled by an individ-
ual’s height as a function of age and covariates genetic risk
(R1 sarcomere variant) and physiologic risk (R2 physio-
logic risk factors).
LVWT
height
 ageþ Riskgenetic þ Riskphysiologic
þ RiskgeneticRiskphysiologic þ Error

individual
age

In this model, the sarcomere genetic risk covariate was
statistically significant (p < 0.05) and age and physiologic
risk were statistically significant (p < 0.001). The result
remained significant when evaluated by empirical permu-
tation as described above.
A significant increase in rate of LV diastolic diameter
change over time was observed in individuals with genetic
risk in the absence of physiologic risk (p < 0.05) but not in
the other groups analyzed (Figure 1B). This might occur
because a subset of the genetic variants predisposes an
individual to a dilated cardiomyopathy phenotype and/
or reflect hemodynamic responses in individuals with
only genetic risk factors. Alternatively, treatments might
have diminished the LV diastolic diameter in individuals
with physiologic risks.
We next sought to evaluate the association between rare
sarcomere variants and adverse cardiovascular-event freeer 7, 2012
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Figure 1. Stratified Framingham Cardiovascular Phenotypes
(A) Longitudinal regression of LVWT scaled to height over time
stratified by genetic risk only (defined by one or more sarcomere
variants in the absence of physiological risk factors), presence of
two or more physiological risk factors (hyperlipidemia, hyperten-
sion, obesity, or diabetes), or the combination of genetic and phys-
iologic risk factors. The inset shows a bar graph of regression line
slopes, with standard deviations.
(B) Longitudinal regression of left ventricular diastolic diameter
(LVDD) scaled to height, stratified as above. A statistically sig-
nificant decline (p < 0.05) is observed between the slope of indi-
viduals with and without genetic risk factors in the absence of
physiologic risk factors.
(C) Kaplan-Meier curves showing age of first adverse cardiovas-
cular event, stratified as described above. Increased risk for first
adverse cardiovascular event conferred by genetic risk factor is
significant (p < .01).survival. To perform this analysis, we stratified individuals
by physiologic and genetic risk between ages 35 and 50,
excluding individuals who did not have a physical exam
in that time period (n ¼ 168) and those individuals who
had a prior cardiovascular event (n ¼ 32). The distribution
of cardiac dimensions in individuals excluded from the
analysis was no different than the overall population.
Significance was determined with a multivariable Cox-
proportional hazards model with physiologic risk (R2
physiologic risk factors) and genetic risk (R1 sarcomereThe Americanvariant) modeled as dichotomous covariate terms as well
as a term for the interaction of the two variables. All three
terms were statistically significant (genetic risk, p < 0.01;
physiologic risk, p < 0.001; genetic/physiologic risk inter-
action term p < 0.05). We evaluated whether the fitted
Cox-proportional hazards regression model adequately
describes the data by testing proportionality of hazards,
influential observations, and nonlinearity assumptions.
Analysis could not be extended beyond the age of 65
because the assumption of proportionality of hazards for
our physiologic risk covariate did not hold beyond 30
years, which is comparable to the longest duration
Framingham Risk Score.25 Significance of the Cox- pro-
portional hazards model result was confirmed through
empirical permutation as described above.
Rare sarcomere variants were found to increase risk for
adverse cardiovascular events in the FHS cohort (Fig-
ure 1C). Comparison of Kaplan-Meier survival curves and
a multivariable Cox proportional hazard model account-
ing for presence of genetic and physiologic risk
factors withmean follow up of 25 years indicated that indi-
viduals with one or more rare nonsynonymous variants
either with or without physiologic risk had significantly
earlier onset of first cardiovascular events (hazard ratio:
2.3; 95% confidence interval: [1.2, 4.1]; p < .01;
Table S7). Remarkably, the significance of this association
is even stronger (hazard ratio: 2.8; 95% confidence
interval: [1.5, 5.1]; p < 0.001) when adverse cardiovascular
events are restricted to those affecting the myocardium
(e.g., angina pectoris, myocardial infarction, coronary
insufficiency, and congestive heart failure). Although 12
out of the 14 first observed cardiovascular disease events
in individuals with genetic risk and no physiologic risk
factors were in diseases of the myocardium as compared
to 32 out of 48 disease events in individuals with no
genetic or physiologic risk factors, a chi-square test failed
to identify significant differences in event distribution
between groups (Table S8). Previous work has linked
cardiac hypertrophy to earlier adverse cardiovascular event
onset of all manifestations of cardiovascular disease,26,27
so it is possible that the increased cardiovascular dimen-
sions in individuals with genetic risk explains this survival
curve. Testing this hypothesis proved inconclusive because
of the small number of individuals in our study with both
genetic risk and observed cardiovascular events.
Our analysis of rare variants in eight sarcomere genes
suggests that rare genetic variants might contribute to
cardiovascular risk assessment in the community. We
were surprised to see that sarcomere protein gene variants
previously described as pathogenic were present in 0.6% of
the general population, twice the estimated prevalence of
HCM.12 Moreover, this fraction of pathogenic variants is
likely an underestimate given our findings that >10% of
the population carries a rare nonsynonymous sarcomere
variant and the possibility that some of these variants are
also pathogenic. On the other hand, we find that the
estimated effect sizes of these variants are smaller whenJournal of Human Genetics 91, 513–519, September 7, 2012 517
ascertained in the general population than was pre-
viously predicted from clinically identified families. Going
forward, functional analyses in combination with compu-
tational and additional clinical data (e.g., assessment of
diastolic function) might better discern pathogenic from
benign rare variants found in the general population.
Such information will be essential for accurate interpreta-
tion of personal genomes. Nevertheless, the association
of sarcomere genetic risk with differences in left ventricular
dimensions and with earlier onset of adverse cardiovas-
cular events (hazard ratio: 2.3) suggests that analysis of
rare variants might potentially be an informative tool in
assessing cardiovascular risk in the general population in
the future.Supplemental Data
Supplemental Data include four figures and eight tables and can be
found with this article online at http://www.cell.com/AJHG.Acknowledgments
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